📰 Ben Brahim News
Page 4 - Ben Brahim News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ben Brahim. Real-time updates on events, politics, business and more.
November 23, 2021
Positive initial data generated in the first six patients treated with TG4050 demonstrate the strong potential of this individualized immunotherapy in ovarian cancer and head and neck cancer- TG4050 induced
June 1, 2021
Tina: New documentary explores successes and struggles of global superstar Issued on: 01/06/2021 - 16:50 ENCORE! © Universal Pictures 14 min A new documentary shines a spotlight on Tina Turners ascent to stardom, as well as her abusive relationship with Ike Turner. It mixes intimate interviews with the now 81-year-old singer-songwriter and those close to her, as well as rare archival footage. FRANCE 24s Jennifer Ben Brahim spoke...
May 27, 2021
Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent")
May 27, 2021
/PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and...
May 26, 2021
Regulatory News: The Combined Ordinary and Extraordinary General Meeting of Transgene's (Paris:TNG) shareholders was held today (May 26, 2021) at 10:00 a.m. at the Company's headquarters (400 boulevard
March 10, 2021
Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022 myvac TG4001 : expanded randomized Phase II trial to start in HPV-positive anogenital cancers, based on encouraging Phase Ib/II data BT-001 Invir.IO platform following the partial sale of the stake in Tasly BioPharmaceuticals in 2020 Conference call in English scheduled today at 6:00 p.m. CET Video conference in French on March 10 at 10:00 a.m. CET (details at the end of the release) R...
March 1, 2021
Provided by Business Wire Mar 1, 2021 6:30 AM UTC Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune...